earnings
confidence high
sentiment positive
materiality 0.75
Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS
Coya Therapeutics, Inc.
2026-Q1 EPS reported
-$0.32
revenue$251,147
- Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).
- Cash and cash equivalents $50.7M as of March 31, 2026.
- FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.
- ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.
- Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M).